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Abstract
Background: The evaluation of imprecision is a key dimension of the grading of the confidence in the estimate.
Grading of Recommendations Assessment, Development and Evaluation (GRADE) gives recommendations on how
to downgrade evidence for imprecision, but authors vary in their use. Trial Sequential Analysis (TSA) has been
advocated for a more reliable assessment of imprecision. We aimed to evaluate reporting of and adherence to
GRADE and to compare the assessment of imprecision of intervention effects assessed by GRADE and TSA in
Cochrane systematic reviews.
Methods: In this cross-sectional study, we included 100 Cochrane reviews irrespective of type of intervention with
a key dichotomous outcome meta-analyzed and assessed by GRADE. The methods and results sections of each
review were assessed for adequacy of imprecision evaluation. We re-analyzed imprecision following the GRADE
Handbook and the TSA Manual.
Results: Overall, only 13.0% of reviews stated the criteria they applied to assess imprecision. The most common
dimensions were the 95% width of the confidence intervals and the optimal information size. Review authors
downgraded 48.0% of key outcomes due to imprecision. When imprecision was re-analyzed following the GRADE
Handbook, 64% of outcomes were downgraded. Agreement between review authors’ assessment and assessment
by the authors of this study was moderate (kappa 0.43, 95% confidence interval [CI] 0.23 to 0.58). TSA downgraded
69.0% outcomes due to imprecision. Agreement between review authors’ GRADE assessment and TSA, irrespective
of downgrading levels, was moderate (kappa 0.43, 95% CI 0.21 to 0.57). Agreement between our GRADE assessment
following the Handbook and TSA was substantial (kappa 0.66, 95% CI 0.49 to 0.79).
Conclusions: In a sample of Cochrane reviews, methods for assessing imprecision were rarely reported. GRADE
according to Handbook guidelines and TSA led to more severe judgment of imprecision rather than GRADE adopted by
reviews’ authors. Cochrane initiatives to improve adherence to GRADE Handbook are warranted. TSA may transparently
assist in such development.
Keywords: Review, Meta-analysis, Bias, Confidence intervals, Epidemiologic methods
* Correspondence: greta.castellini@unimi.it
1Department of Biomedical Sciences for Health, University of Milan, via Pascal
36, 20133 Milan, Italy
2Unit of Clinical Epidemiology, IRCCS Galeazzi Orthopedic Institute, via
Galeazzi, 4, 20161 Milan, Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Castellini et al. Systematic Reviews  (2018) 7:110 
https://doi.org/10.1186/s13643-018-0770-1
Background
The clinical sciences attempt to solve uncertainties and
disagreements on the effectiveness of interventions by
making research findings valid and interpretable. The
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) system has gained momentum
as an internationally recognized framework to assess the
quality of evidence systematically and transparently [1].
The GRADE approach suggests evaluating five key dimen-
sions that may affect our confidence in intervention effects:
risks of bias (risks of systematic errors), imprecision (risks
of random errors), inconsistency, indirectness, and publica-
tion bias [2, 3]. Imprecision, along with risk of bias, are
the most common domains associated with GRADE
downgrading of overall evidence quality or certainty [4].
Systematic reviews employ multiple parameters to
evaluate imprecision: accrued sample size, required or
optimal information size (OIS) (meta-analytic “sample
size”), alpha, beta, confidence intervals of the overall effect,
and specified critical margins of “no effect,” “important
benefit,” or “important harm” [2]. GRADE combines all
components in a simple rule: “If the optimal information
size criterion is not met, rate down for imprecision, unless
the sample size is very large (at least 2000, and perhaps
4000 patients); if the optimal information size criterion is
met and the 95% confidence interval (CI) excludes no
effect, do not rate down for imprecision; if the optimal
information size criterion is met, and the 95% CI overlaps
no effect, rate down for imprecision if the CI fails to
exclude important benefit or important harm” [5, 6].
The GRADE rules of thumb are based on broad as-
sumptions and generalities across medical fields. The most
relevant advantage is facilitating the trustworthiness of
recommendations, enabling users to reflect on the sample
as a basis for recommendations. However, rating impreci-
sion in isolation, without a formal evaluation of accrued
sample and magnitude of effects (e.g. benefits or harms),
would be hazardous [5, 7]. Because random errors are a
frequent cause of erroneous estimation of treatment effect,
often in small meta-analyses [8], several authors have
highlighted the need to adjust the statistical threshold and
calculate a required information size in meta-analyses
to increase the validity and reliability of its conclusions
[9, 10]. Among the techniques that can control for the
risk of random error in the context of sparse data [11],
Trial Sequential Analysis (TSA) is often used to control
for spurious findings [12, 13] and is currently suggested as
a potential supplement for a more throughout assessment
of imprecision when using the GRADE system [14].
Objectives
We conducted an empirical assessment of a sample of
Cochrane systematic reviews (SRs) in which the focus
was imprecision as a threat to validity. We investigated
the reporting of and the adherence to GRADE in assessing
imprecision, the expected and observed downgrading of
evidence, and the reasons for downgrading. Moreover,
after having estimated the Cochrane authors’ handling
of GRADE and imprecision, we applied ourselves GRADE
assessment of imprecision following the GRADE Handbook
guidelines [6] and TSA following the TSA Manual [15] to
independently replicate the assessments of imprecision.
Methods
Search strategy
For this cross-sectional study, Cochrane systematic reviews
were sampled from the Cochrane Database of Systematic
Reviews [16]. We purposively retrieved 100 reviews in
reverse chronological order starting at the time of our
search, 23 February 2017. The most current reviews, i.e.
the latest published, were selected to ensure inclusion of
the most recent publications following the introduction of
GRADE [1] and its detailed guidance [2, 3, 5, 6]. The
nature of this study was explorative, and no sample size
was calculated.
Eligibility criteria and study selection
Titles and abstracts were screened for eligibility in their
chronological order of publication. Full texts were retrieved
and evaluated against our inclusion criteria by one investi-
gator. A second investigator checked all eligible records,
and a final list was agreed. Cochrane systematic reviews
were considered eligible for inclusion if (1) they were
reviews of interventions, (2) they meta-analyzed at least
two randomized controlled trials (RCTs) for a dichot-
omous outcome, and (3) the dichotomous outcome was
listed in the summary of findings (SoF) table.
We excluded diagnosis/prognosis reviews, studies on
health service organization, overviews of systematic reviews
and network meta-analyses, and meta-analyses with only
uninformative trials (i.e., with no events). The unit of ana-
lysis was one outcome for each review: either the primary
outcome or the first outcome meta-analyzed and listed in
the SoF. We reasoned a priori that this outcome would
most likely provide the basis for calculating sample size and
orient clinical decision-making.
Data collection
General characteristics and reporting of GRADE in Cochrane
reviews
Two investigators independently extracted data from all
selected reviews. A third investigator resolved disagree-
ments. We used a standardized ad hoc data collection
form that we piloted on the first five Cochrane reviews and
then revised according to problems identified. For each
review, we sought general information (e.g., author, contact
author country, Cochrane review group name, new or
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updated review, type of intervention—pharmacological
or non-pharmacological).
We evaluated what authors reported in the review
methods section for assessment of imprecision. In particu-
lar, we wanted to determine whether the authors stated they
had assessed imprecision and how (e.g., required or optimal
information size, benefit/harm thresholds, width of 95%
confidence intervals (CI), use of TSA) and in what way they
planned to use imprecision assessment (e.g., evidence is
downgraded when the required or optimal information size
is not reached). We then recorded the grading of impreci-
sion of the outcome selected from the SoF table and the
reasons for downgrading. In some cases, we searched other
sections of the full-text article for additional information.
Adherence to GRADE
We judged whether the review authors adhered to
GRADE guidance for downgrading or non-downgrading
evidence for imprecision. To determine whether the
imprecision evaluation was appropriate (e.g., expected
and observed downgrading of evidence), we consulted
the instructions for downgrading for imprecision and
re-assessed the optimal information size as suggested by
the GRADE Handbook guidelines [17]. For each review,
we calculated the optimal information size in which we
assumed an alpha of 0.05, a beta of 0.20, and an a priori
anticipated intervention effect—e.g., risk ratio reduction
(RRR) or improvement—defined using the clinically
relevant threshold reported by the review authors or,
when not stated, the RRR suggested by GRADE authors,
as a default threshold of 25% [3], and the control event
proportion of the meta-analysis. We used the normo-
gram for events proposed by Guyatt et al. to determine
the expected optimal information size [2]. Finally, we
determined whether the reviewers incorporated and
reported the imprecision assessment in their evaluation
of evidence quality.
Agreement between GRADE assessment of imprecision and
TSA
We evaluated agreement between downgrading of evidence
as proposed in the original reviews and those performed by
the authors of this article, and that resulting from TSA. For
each review, we performed overarching TSAs: for each
outcome, we re-analyzed all trials that had been originally
included in the meta-analysis. Data were synthesized using
the same effect size with its 95% confidence interval (CI)
and the same meta-analytic technique (i.e., random effects
or fixed effect models), applying the reported statistical
heterogeneity (I2 value). Each trial was sequentially added
in the TSA by publication year; this created a series of time
points that formed the basis of the cumulative analysis. All
TSAs were performed using TSA software (v 0.9.5.5 Beta)
[18]. For each review, we calculated the diversity-adjusted
required information size (DARIS) using, again, an alpha of
0.05, a beta of 0.20, and a RRR as defined by the review
authors or the default threshold of 25%, and the control
event proportion. When a random effects model was
chosen, between-trial variability was taken into account by
adjusting the required information size with the diversity
(D2) originating from the meta-analysis of trials [19]. The
Lan-DeMets trial sequential monitoring boundaries based
on O’Brien-Fleming α-spending function was used [13, 20].
The cumulative Z-curve (the series of Z-statistics after each
consecutive trial) was calculated and plotted against these
monitoring boundaries.
In our primary analysis, we assumed for TSA minimal
important or realistic anticipated intervention effects for
all outcomes. If, following TSA methods [10], none of
the sequential boundaries for benefit, harm, or futility
were crossed, imprecision was downgraded by two levels
(Additional file 1 reports TSA judgment).
Data analysis
The data were summarized with descriptive statistics.
Absolute and relative frequencies for categorical items
and median and interquartile range (IQR) for continuous
items were used. We reported adherence to GRADE
through figures and agreement between the assessments
involving the use of GRADE and TSA in contingency
tables, with calculation of Cohen’s kappa [21].
Agreement between GRADE imprecision assessment
performed by the review authors and TSA was rated on
the ordinal scale as: 0, not downgraded; 1, downgraded
by 1 level; 2, downgraded by 2 levels. Moreover, we di-
chotomized the ordinal scale into “downgraded” and
“not downgraded” for imprecision to evaluate the agree-
ment irrespective of level of downgrading. Interpretation
of agreement strength (k-values) was made according to
the scale devised by Landis and Koch: < 0.00 poor, 0–0.20
slight, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80
substantial, and 0.81–1.00 almost perfect [22].
Univariable logistic regression was performed to investi-
gate the impact of variables on downgrading for impreci-
sion (dependent variable): Cochrane Group, the country of
the contact author, type of intervention, number of patients
included in the meta-analysis, heterogeneity among trials,
and meta-analysis technique (random effects or fixed effect
models). Each method, GRADE assessment of imprecision
by the review authors, GRADE performed by the authors
of this article, and TSA, was separately assessed and
one variable evaluated at a time. The impact of these
variables on the agreement between the methods was
then tested.
For hypothesis testing, a probability value of < .05 was
considered statistically significant. All statistical tests
were two-sided. Stata statistical software was used for all
statistical analyses [23].
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Sensitivity analysis
TSAs were replicated using RRRs of (A) 20% and (B) 30%,
keeping all other assumptions the same. The concordance
between the GRADE judgment on imprecision by the
review authors and the TSA assessment was calculated
irrespective of the levels of downgrading to determine
whether the choice of the anticipated intervention effect
affected the agreement.
Results
Characteristics of Cochrane reviews
We included 100 out of 216 potentially eligible Cochrane
systematic reviews published in 2017 (issues 1 and 2) and
2016 (issues 12 and 11) of The Cochrane Library (Fig. 1),
involving 36 (67.9%) out of 53 different Cochrane groups.
Figure 1 shows the flow chart of reviews’ selection with
reasons for exclusion. Additional file 2 reports included
reviews and their main characteristics.
The three most active review groups were pregnancy
and childbirth (n = 13 reviews), neonatal (n = 11 reviews),
and heart (n = 8 reviews). The corresponding authors
were based in the UK (n = 28 reviews), Australia (n = 15
reviews), or Canada (n = 11 reviews). Sixty-one Cochrane
reviews were updates of previous reviews. Table 1 presents
the general characteristics of the reviews.
Overall, meta-analyses on the selected outcome were
performed with a median of five RCTs (IQR, 2 to 9 RCTs;
range, 2 to 30 RCTs). Most meta-analyses (81.0%) reported
an effect measure expressed as risk ratio, 17.0% used the
odds ratio, and only 2.0% reported the risk difference. Half
of the SRs (51.0%) achieved statistically significant results
according to the naïve 95% CI. The median heterogeneity
of the meta-analyses was 12.0% (IQR, 0.0 to 49.0%; range,
0.0 to 98.0%).
Reporting of GRADE in Cochrane reviews
Nearly all (96.0%) of the reviews referred to GRADE in
their methods section (Table 2). Of the four reviews that
did not mention GRADE but performed it, two presented
some information in the discussion. Very few (13.0%) of
the reviews that graded the evidence reported the criteria
they applied to assess imprecision. The most common
imprecision components were width of 95% CI (8.0%) and
optimal information size referred to participants (4.0%).
Ten reviews combined at least two criteria to assess
imprecision. Only two reviews reported a comprehensive
list of reasons behind imprecision judgment, thus allowing
Potentially eligible Cochrane systematic reviews (n=216) 
Eligible Cochrane systematic reviews (n=100)
Excluded reviews (n=116):
- 1 methodological review
- 1 qualitative review
- 9 withdrawn reviews
- 5 overview reviews
- 2 diagnostic reviews
- 39 reviews with 1 or no trials
- 2 individual patient data reviews
- 19 reviews with no dichotomous 
outcomes
- 22 reviews with no meta-analysis
- 5 reviews with no SoF table
- 11 reviews on other intervention (i.e. 
public health management) 
Fig. 1 Flow chart of systematic reviews
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for full replication. Two other reviews planned and con-
ducted a TSA. Neither the publisher Cochrane Group nor
the country of the contact author influenced the reporting
of imprecision assessment (univariable logistic regressions,
respectively: Cochrane Group, p = 0.716; country of
contact author, p = 0.782).
The quality of the meta-analyzed dichotomous outcomes
was often graded as low (41.0%), with few outcomes reach-
ing high quality (9.0%). Few reviews clearly stated on which
criteria their assessment of imprecision was based. However,
lack of details on how imprecision was assessed did not
prevent the systematic reviewers to evaluate it, completing
the SoF. Overall, almost half of the outcomes (48.0%) were
downgraded for imprecision, with only six reviews down-
grading imprecision by two levels. The most frequent
reasons for downgrading due to imprecision were low num-
ber of events or small sample size (26.0%) and wide 95% CIs
(25.0%). Six outcomes were downgraded due to imprecision,
but no reason was reported in the SoF tables or full-text.
Adherence to GRADE Handbook instructions
When the authors of this article followed the GRADE
Handbook instructions on how to replicate assessment
and evaluate adherence, 64 outcomes were downgraded
due to imprecision. Sixty-six did not meet the OIS for
events. Overall, in 30.0% of reviews, judgment of outcomes
differed between the review authors and the authors of this
article who followed the GRADE Handbook (Figs. 2 and 3).
Cohen’s kappa coefficient between the grading of im-
precision as proposed by the original authors and as
re-analyzed by us following the GRADE Handbook was
0.43 (95% CI 0.23 to 0.58), which expressed moderate
strength of agreement.
Imprecision by TSA
The anticipated intervention effect was reported only by
12 reviews. For the other reviews, we adopted a 25%
RRR to calculate the required information size. Overall,
69 outcomes were downgraded due to imprecision by
applying TSA (downgrading by two levels since the antici-
pated intervention effect was assumed as being realistic).
Indeed, five more outcomes were downgraded for impre-
cision by applying TSA as compared to using the
GRADE Handbook instructions. The required informa-
tion size was reached by 17 meta-analyses (17.0%). In
the remaining 83.0%, the median number of participants
needed to reach the required information size was 4187
(IQR, 1467 to 11,104 participants).
Agreement between GRADE by review authors and TSA
Weighted Cohen’s kappa coefficient showing agreement
between GRADE performed by review authors and TSA
was 0.20 (95% CI 0.11 to 0.30). The coefficient expressed
slight agreement (Table 3).
Table 2 Approaches to assessment of imprecision and formal
quantitative analyses of imprecision in Cochrane systematic
reviews. Values are numbers
Reported
(no. of reviews out of 100)
Methods section
Reviewers carried out GRADE assessment 96
Criteria considered for assessing
imprecision?
13
- Width of 95% confidence interval 8
- Optimal information size—no. of
participants
4
- Optimal information size—no. of events 1
- Threshold for benefit or harm 1
- Trial Sequential Analysis 2
Results section
Optimal information size—no. of events 2
Optimal information size—no. of
participants
8
Thresholds for benefit or harm 15
Trial Sequential Analysis 2
Table 1 General characteristics of the 100 Cochrane systematic
reviews
Characteristics Value (no. of reviews)
No. of countries (total no.) 22
Top five countries
- UK 28
- Australia 15
- Canada 11
- China 7
- Italy 6
No. of Cochrane groups (total no,) 36
Top five Cochrane groups
- Cochrane Pregnancy and Childbirth Group 13
- Cochrane Neonatal Group 11
- Cochrane Heart Group 8
- Cochrane Airways Group 6
- Cochrane Gynecology and Fertility Group 6
Status of systematic reviews (out of 100)
- Updated 61
- New 39
Type of intervention (out of 100)
- Pharmacological 54
- Non-pharmacological 46
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Considering only the outcomes downgraded or not
downgraded due to imprecision, irrespective of levels,
unweighted Cohen’s kappa coefficient was 0.43 (95% CI
0.21 to 0.57), expressing moderate strength of agreement
(Table 4).
Agreement between GRADE by authors of this article and
TSA
The imprecision evaluated by the authors of this article
following the GRADE Handbook guidelines and by TSA
was similar: unweighted Cohen’s kappa coefficient was 0.66
(95% CI 0.49 to 0.79), expressing substantial agreement
(Table 4).
Results of logistic regression analyses
In the univariable logistic regression analysis, the type of
the intervention (GRADE by review authors: p = 0.65;
TSA p = 0.78), the number of patients included in the
meta-analysis (GRADE by the review authors: p = 0.08;
TSA p = 0.07), the heterogeneity (GRADE by review au-
thors: p = 0.12; TSA p = 0.38), and the meta-analysis
technique (random effects or fixed effect models) (GRADE
by review authors: p = 0.86; TSA p = 0.29) were not associ-
ated with downgrading due to imprecision.
When GRADE assessment of imprecision carried out
by the review authors was compared to TSA assessment
and GRADE replicated by the authors of this article
according to the Handbook guidelines, it seemed that
OIS met
34 primary outcomes
CI excludes no effect
Review authors: 17 not downgraded
GRADE Handbook: 17 not downgraded
CI includes no effect
17
CI fails to exclude important benefit or 
important harm
Review authors: 2 downgraded and 2 not 
downgraded
GRADE Handbook: 4 downgraded
CI excludes important benefit and harm
Review authors: 3 downgraded and 10 not 
downgraded
GRADE Handbook: 13 not downgraded
Fig. 2 Primary outcomes that met the OIS—number of events: comparing GRADE assessment of imprecision carried out by review authors with
GRADE carried out by the authors of this article following GRADE Handbook guidelines
OIS not met
66 primary outcomes
At least 2000 participants 
Review authors: 4 downgraded and 2 not 
downgraded
GRADE Handbook: 6 not downgraded
Less than 2000 participants
Review authors: 39 downgraded and 21 not 
downgraded 
GRADE Handbook: 60 downgraded
Fig. 3 Primary outcomes that did not meet the OIS—number of events: comparing GRADE assessment of imprecision carried out by review
authors with GRADE carried out by the authors of this article following GRADE Handbook guidelines
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the meta-analytic model (random or fixed effect) might
influence the agreement in both cases (p= 0.04 and p= 0.09,
respectively), whereas the number of patients might
influence only agreement between GRADE by the authors
of this article and TSA (p = 0.01).
Logistic regression tables are added as Additional file 3.
Sensitivity analysis
TSAs with an anticipated intervention effect of 30% RRR
revealed 60.0% of the SRs downgraded due to imprecision.
When the anticipated intervention effect was lowered to
20% RRR, the percentage of SRs downgraded due to
imprecision increased to 73.0%. Cohen’s kappa coeffi-
cients, expressing downgrading or not due to imprecision,
irrespectively of the downgrading levels (by 1 or 2), did
not change much: coefficients 0.43 (95% CI, 0.22 to 0.58)
and 0.43 (95% CI, 0.20 to 0.56), respectively.
Discussion
Given the implications of imprecision evaluation for
recommending health care interventions as standard of
care or cautionary noting that additional clinical trials
are warranted, it is expected that imprecision be trans-
parently evaluated and reported. There remains ample
room for improvement, however. Almost half of the out-
comes were downgraded due to imprecision, but only
about 1 in 10 reviews reported the criteria to downgrade
imprecision. The width of 95% of confidence intervals
and the number of study participants were the most
common criteria to infer downgrading due to impreci-
sion. One third of the conclusions that did not down-
grade the evidence for imprecision would have been
contradicted based on GRADE assessment of impreci-
sion following the GRADE Handbook or TSA if these
methods had been applied. This was mainly because
GRADE evaluation by the review authors was more leni-
ent and also because the number of patients included in
the meta-analyses was often insufficient to make any
definitive conclusion.
The GRADE approach and TSA have different conno-
tations that might influence the judgment process. While
GRADE is defined as “a semi quantitative approach that
encompasses imprecision besides the other certainty
domains” and has intrinsic subjectivity [5], TSA can be
viewed as a purely quantitative and objective approach
[10]. Despite their differences, the agreement between
the two approaches was substantial. Nonetheless, the
two methods give different weight to the extent of
imprecision. TSA tended toward more severe judgment,
while GRADE seemed to be more easily applied by the
review authors, resulting in overestimation of the certainty
of evidence. When imprecision is rated as negligible
(i.e., the true effect plausibly lies within the 95% CI),
it is more likely that the effect estimates can be
trusted and evidence quality rated highly. TSA will
allow the reader to gauge the extent of confidence on
imprecision of primary results of meta-analyses,
though it might also be perceived as too radical by some.
With a GRADE approach, reviewers’ decisions on down-
grading are more open to subjective decisions. To guide
such decisions, further research is warranted on optimal
information size and of different types of interventions
under different circumstances.
Strengths and weaknesses of the study
This study has several limitations. We included only
Cochrane reviews of health care interventions, a fairly
homogeneous but partial sample of systematic reviews
published in the medical literature. Reviews published in
other medical journals might provide different results.
However, since Cochrane strongly encourages the use of
the GRADE approach, including imprecision, it seems
implausible that other journals would perform better.
Our analyses are valid for pooled results and restricted
to dichotomous outcomes, limiting the generalizability
of our results. However, in the medical literature, two
Table 3 Concordance in downgrading due to imprecision by 1
and 2 levels between GRADE carried out by the review authors
and with TSA
TSA
Not
downgraded
Downgraded
by 1 level
Downgraded
by 2 levels
Total
GRADE by review authors
Not
downgraded
27 0 25 52
Downgraded
by 1 level
3 0 39 42
Downgraded
by 2 levels
1 0 5 6
Total 31 0 69 100
Table 4 Concordance in downgrading due to imprecision
between GRADE carried out by review authors, by authors of
this article, and with TSA
TSA
Not downgraded Downgraded Total
GRADE by review authors
Not downgraded 27 25 52
Downgraded 4 44 48
Total 31 69 100
GRADE by the authors of this article
Not downgraded 26 10 36
Downgraded 5 59 64
Total 31 69 100
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thirds of primary outcomes reported by systematic re-
views are dichotomous [24]. Besides, calculation and
definition of a clinical threshold for continuous out-
comes, i.e., the minimal important differences or min-
imal detectable changes, remain ambiguous and
unclear [25, 26]. Furthermore, our logistic regression
results may be under-powered to detect any signifi-
cant factor, due to the limited number of studies
included in the analysis.
While our analysis was protected against confounding
by disease area and type of intervention because it is based
on a sample of meta-analyses irrespective of interventions,
it may still have been confounded by other meta-analysis
characteristics. Given the wide diversity of the studies in-
cluded, the quantitative results are suggestive and might
change in the future when GRADE and Cochrane propose
methods and policies that strengthen imprecision assess-
ment. Furthermore, imprecision assessment may vary be-
tween research areas (i.e., type of interventions),
becoming speculative in fields where trials and reviews
are too small to permit exploration of imprecision.
When we evaluated the conclusiveness of evidence by
TSA in studies where the anticipated treatment effect
was not reported, we could not directly assess the au-
thors’ assumptions on relevant intervention effects. We
chose one arbitrary hypothesis when we recalculated the
required information size based on a 25% relative risk
reduction or improvement, which might be unrealistic
for some outcomes. Nevertheless, the proportion of
primary outcomes downgraded for imprecision did not
change substantially when we applied different thresh-
olds for benefits in our sensitivity analyses. Moreover,
we only used a two-level downgrading approach when
our TSA did not show benefit, harm, or futility. By, e.g.,
employing the Trial Sequential Analysis-adjusted
confidence intervals, this simple approach could have
been refined.
As well, our results are based on our subjective applica-
tion of the GRADE approach following the GRADE
Handbook, which would then influence the assessments
we made between the methods.
Despite these limitations, this project aspires to be a
step toward optimized assessment and interpretation of
the certainty of evidence regarding imprecision. Recently,
evidence synthesis has evolved into a dynamic process. A
new concept of systematic reviews, living systematic
reviews, has been introduced [27]. In this context, TSA
has been suggested as a valid method to assess constantly
updated evidence [12] since it can offer constantly
updating of optimal information size as new trials are
added. This dynamicity could affect the imprecision
domain, with assessment more closely related to what
has been reached for a specific condition, outcome, and
intervention at a certain time point.
Implications for systematic reviewers
As part of their mandate to identify potentially effective
interventions, systematic reviewers should include precision
as a key dimension to evaluate, particularly in situations
where uncertainty about the ratio between benefits and
harms is high and where new trial data may influence the
summary judgment of the review [28]. More detailed
guidance from PRISMA and PRISMA-P could facilitate
the analysis and reporting of imprecision [29, 30]. There is
room for better standardization of approaches and inclu-
sion of quantitative methods, such as TSA, to formally
evaluate imprecision.
Implications for clinicians
Imprecision assessment seems to be based on GRADE-
ing criteria that vary considerably in meaning, value, or
boundaries depending on context or conditions. Incom-
plete or vague imprecision assessment supports the nat-
ural tendency to simplify a review’s findings about an
intervention as positive or negative and to over-rely on
P values [31]. Instead, clinicians using evidence to orient
their practice should interpret imprecision as a dynamic
and often uncertain dimension that requires thorough
examination of all of the evidence, including size of the
trials, number of participants with outcomes, and
heterogeneity (diversity) across trials. TSA offers the
means to model heterogeneity and estimate optimal
information size based on different heterogeneity
thresholds.
Future research
Further research is needed to determine whether accurate
assessment of imprecision might change the clinicians’
perception about the definitive effectiveness of interven-
tions. It would be beneficial to develop an international
database of prospectively updated TSAs for all health
interventions, where people can easily consult the
progress of research. This might also help to diminish
“the butterfly behavior of researchers” from moving
onto the next research question before the previous
quest has been fully exploited [32].
Conclusions
A significant lack of reporting of and adherence to
GRADE was observed in Cochrane systematic reviews.
Stricter adherence to GRADE Handbook guidelines
and/or adoption of TSA would have led to more fre-
quent downgrading of the quality of evidence. Our
findings reiterate the need for a more reliable applica-
tion of GRADE in Cochrane and non-Cochrane reviews
for the assessment of imprecision. The reasons for
downgrading should be defined following a more struc-
tured reporting system. Initiatives to improve adher-
ence to GRADE indications are warranted to ensure
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high-quality systematic reviews. Cochrane groups, peer
reviewers, and editors need to be more supportive dur-
ing the GRADE assessment process as it is still difficult
to apply and requires a structured reporting policy to
ensure transparency and intelligibility in the process.
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